First quarter revenue growth for IBO’s Laboratory Instrument Sales Index slowed to 0.7%, 1.9% excluding currency, to $5,912 million. Operating profit declined 2.9% to $1,215 million, and operating margin fell 80 basis points to 17.9% of sales. Financial estimates are included for Oxford Instruments, Spectris and Tecan, which have yet to report first quarter financial […]
Investors may find solace in the correlation between compensation awards and financial performance at the 37 firms in IBO’s Stock Indexes. In fiscal 2012 (FY12), total compensation packages declined for 28 of the 44 presidents, CEOs or heads of dedicated business units at these companies who have held their respective roles for more than one […]
Instrument and lab product company executives appear more optimistic about sales prospects now than they did in fall 2012, according to the latest results of the IBO Business Climate Survey. This is despite the US budget sequestration and recent downgrade in expectations for world GDP growth by the International Monetary Fund (IMF). In April, the […]
Revenues for 598 publicly held biotech companies grew 8.1% last year to $89.8 billion, compared to 10% in 2011. R&D expenditures increased 5.4% to $25.3 billion, compared to 9% in 2011. Revenues from US public firms increased 8.3% to $63.7 billion, and R&D spending grew 7.3% to $19.3 billion. In 2011, US public firms’ sales […]
According to the International Energy Agency, the world is making little progress in producing cleaner energy. Despite the development of cleaner energy sources and more energy efficient technologies, the use of fossil fuels and coal continues to dominate. Renewables accounted for 19% of electricity generation in 2012. Among renewables, solar photovoltaic capacity grew 42% to […]
In 2012, domestic and foreign R&D spending by members of the Pharmaceutical Research and Manufacturers of America (PhRMA) declined for the second year in a row to $48,485 million, a 0.3% decrease. Domestic expenditures increased 1.2%, and spending abroad dropped 4.9% to account for 76% and 24% of PhRMA members’ R&D spending, respectively. As a […]
The first of IBO’s biannual new laboratory roundup focuses on new facilities for cancer treatment and research, along with new genetically modified (GM) crop labs and consumer products labs. In addition, the table on page 6 highlights plans for new labs for the automotive, pharmaceutical and semiconductor industries. Three organizations, including two universities, have announced […]
The EPA proposed a rule to lower air pollution from vehicles. The Tier 3 Motor Vehicle Emission and Fuel Standards will reduce the sulfur content of gas to 10 ppm on an annual average basis starting in 2017. The vehicle emission standards will be phased in, affecting vehicle models produced between 2017 and 2025. The […]
The Obama Administration announced plans for the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, for which the president will request $100 million in funding for fiscal 2014. The Initiative will seek to develop technologies to image individual brain cells and neural-circuit interactions with the goal of improving the treatment of brain disorders. The budget […]
A survey by Booz & Company of drug company executives, experts and its own staff concluded that a tailored approach to local markets is needed for pharmaceutical firms in emerging markets. In 2016, emerging markets are forecast to account for 30% of the $1,190 billion worldwide pharmaceutical market, up from 20% in 2011. Among emerging […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
